Neuralstem (NASDAQ: CUR) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for Neuralstem and Marinus Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuralstem 0 0 0 0 N/A
Marinus Pharmaceuticals 0 0 1 0 3.00

Neuralstem presently has a consensus price target of $3.18, indicating a potential upside of 194.44%. Marinus Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 70.28%. Given Neuralstem’s higher possible upside, equities research analysts plainly believe Neuralstem is more favorable than Marinus Pharmaceuticals.

Profitability

This table compares Neuralstem and Marinus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuralstem -154,347.81% -148.94% -84.85%
Marinus Pharmaceuticals N/A -67.76% -55.65%

Insider & Institutional Ownership

5.8% of Neuralstem shares are owned by institutional investors. Comparatively, 19.0% of Marinus Pharmaceuticals shares are owned by institutional investors. 15.4% of Neuralstem shares are owned by insiders. Comparatively, 6.4% of Marinus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Neuralstem and Marinus Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Neuralstem $20,000.00 818.10 -$21.07 million ($1.66) -0.65
Marinus Pharmaceuticals N/A N/A -$28.64 million ($0.93) -6.95

Neuralstem has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuralstem, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Neuralstem has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.

Summary

Marinus Pharmaceuticals beats Neuralstem on 7 of the 11 factors compared between the two stocks.

About Neuralstem

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.